Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Acquisition

10 Jul 2023 07:00

RNS Number : 4010F
Sopheon PLC
10 July 2023
 

SOPHEON PLC

("Sopheon" the "Company" or the "Group")

 

Acquisition of Prodex business expands Sopheon's global footprint

Sopheon plc, the InnovationOps software company, is pleased to announce the acquisition of the business and assets of Prodex Systems Australasia ("Prodex"), a specialist provider of innovation software and consulting based in Brisbane, Australia.

Now doing business as Sopheon Asia Pacific, the former Prodex business is focused on markets in Australia, New Zealand and South-East Asia and has a number of customers in the region from the food and beverage, chemicals and mining sectors. The acquired business has been Sopheon's reseller in Australia for over a decade and is a healthy and profitable business with revenues for the year ended June 2022 of AUD $1.5m with EBIT of AUD $0.15m. Financials for the year just ended are expected to be at broadly similar levels, with good pipeline visibility for the remainder of 2023. Historically, approximately AUD $0.3m of Prodex revenues have been included in Sopheon's revenues annually, through reseller recharges.

Rationale for acquisition

In the previous 18 months Sopheon has completed two M&A transactions with the acquisition and integration of ROI Blueprints and Solverboard, both of which brought important technology assets to the Group that have now been further developed and launched as Acclaim Projects and Acclaim Ideas, respectively. Alongside internally developed Acclaim Products, the launch of these new solutions expands Sopheon's addressable market by an estimated $2bn and boosts the Group's position as the leading software vendor focused on operationalizing the business of innovation.

As signposted in previous announcements, we have turned our attention to leveraging M&A to add revenue and geographical footprint. The acquisition of the Prodex business, that we know very well thanks to many years of working closely together, brings the group a strong and stable platform to advance customer acquisition and growth in the world's most dynamic region, giving the group a truly global footprint. Prodex, led by Gerard Ryan, has built an enviable reputation and an impressive roster of customers.

Deal structure and consideration

The transaction was structured as transfer of business and assets into a new company immediately acquired by Sopheon. The consideration comprises AUD $1m of which two thirds is payable immediately in cash, and the remainder over three years as contingent deferred consideration tied to baseline performance metrics. An additional contingent earn-out of up to a maximum of AUD $1.2m is also payable over the next three years, tied to revenue and EBIT growth objectives. Up to 50% of the deferred and earn-out consideration may be satisfied in Sopheon shares issued at £5.63 per share being the average closing price of the two weeks preceding the signature of the agreement. The cash consideration component of the acquisition is being funded out of existing and healthy cash resources. The share consideration elements will be subject to orderly market provisions.

 

Greg Coticchia, CEO of Sopheon, said: "This is Sopheon's third acquisition in 19 months and the latest evidence of the strong momentum that our company is experiencing. With companies throughout South-East Asia increasing their innovation investments, it's fitting that Sopheon's first acquisition to expand our geographic presence be in this expanding market. Prodex, a long-time reseller of Accolade, assists innovative and successful companies to make better, quicker decisions and increase speed to market. Sopheon's innovation leadership continues to expand as a result of our consistent growth in product offerings, customer implementations and global reach."

 

Prodex founder and CEO Gerard Ryan added: "The transition for Prodex to become a Sopheon entity is an exciting extension of the reseller agreement we have had in place for many years. We are already working with Sopheon in Australia, New Zealand, and Thailand with market development plans in place for the wider South-East Asian region. We're excited by the synergy of immediate geographic expansion for Sopheon in this highly innovative and high-growth region, while also enabling true 24/7 coverage for Sopheon's global customer base."

 

 

For further information contact:

Andy Michuda (Executive Chairman)Arif Karimjee (CFO)

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes/Abigail Kelly/George Dollemore (Corporate Finance)

Alice Lane / Sunila de Silva (ECM)

finnCap

+ 44 (0) 20 7220 0500

 

Sopheon®, Accolade® and Acclaim™ are trademarks of Sopheon plc. All other trademarks are the property of their respective owners.

About Sopheon. Sopheon (LSE: SPE) empowers organizations to change the world while achieving exceptional long-term revenue growth and profitability. By operationalizing the entire innovation life cycle, Accolade® and Acclaim™ software and expertise enable innovation, product and project professionals to accomplish the full range of InnovationOps tasks to drive innovation at scale. Sopheon's industry leadership was highlighted in the comprehensive MarketsandMarkets™ report on the Innovation Management market, in which Sopheon was listed in the "Stars" category, the highest recognition. Sopheon's solutions have been implemented by hundreds of blue-chip customers with over 137,000 users in 50 countries. Sopheon is listed on the AIM Market of the London Stock Exchange. For more information, please visit www.sopheon.com.  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQNKOBKABKDKOK
Date   Source Headline
27th Jan 20117:00 amPRNTrading Statement
9th Dec 20107:00 amPRNAmendment to the Terms of Convertible Loan Stock
16th Nov 20107:00 amPRNContract Win
4th Nov 20107:00 amPRNInterim Management Statement
27th Aug 201010:30 amPRNGrant of Options
26th Aug 20107:00 amPRNHalf-yearly Report
22nd Jul 20107:00 amRNSTrading Update
15th Jun 20105:31 pmPRNResult of AGM
15th Jun 20107:00 amPRNAGM Statement
18th May 20107:00 amRNSAfton Chemical Selects Idea Lab
6th May 20107:00 amPRNInterim Management Statement
25th Mar 20107:00 amPRNFinal Results
22nd Mar 20107:00 amRNSiSUSTAINT Alliance Launched
3rd Feb 20107:00 amRNSSopheon Team wins TARDEC Contract
28th Jan 20107:00 amPRNTrading Update
24th Dec 20097:01 amRNSExtension of GEM Equity Line
2nd Dec 20097:00 amRNSVision Strategist Version 5.0 Launched
3rd Nov 20097:00 amPRNInterim Management Statement
2nd Oct 20093:43 pmPRNISSUE OF CONVERTIBLE LOAN STOCK
27th Aug 20097:00 amPRNHalf-yearly Report
16th Jun 200912:34 pmPRNResult of AGM
16th Jun 20097:00 amPRNAGM Statement
19th May 20097:00 amPRNProduct Launch
7th May 20097:00 amPRNInterim Management Statement
26th Mar 20097:00 amPRNFinal Results
18th Mar 20097:00 amRNSBostik Implements Sopheon's Accolade System
11th Mar 20097:00 amRNSContract Win
11th Feb 20097:00 amRNSEnhanced Version of Accolade? Launched
28th Jan 20097:00 amPRNTrading Update
21st Jan 20097:00 amRNSSopheon Partners with Maxsoft
4th Nov 20087:00 amPRNInterim Management Statement
28th Aug 20087:00 amPRNHalf-yearly Report
27th Jun 20083:47 pmPRNDirector/PDMR Shareholding
25th Jun 20087:00 amPRNGrowth Milestone
10th Jun 20087:00 amPRNAGM Statement
16th May 20087:00 amPRNDirector/PDMR Shareholding
15th May 20087:00 amPRNInterim Management Statement
6th May 200810:00 amPRNNotice of AGM
29th Apr 20087:02 amRNSContract Win
1st Apr 200810:00 amPRNGrant of Options
27th Mar 20087:00 amPRNFinal Results
6th Feb 20087:01 amRNSProduct Development
25th Jan 20087:00 amPRNTrading Update
21st Dec 200710:30 amPRNTrading Update
25th Oct 20077:00 amPRNTrading Update
16th Oct 20072:38 pmBUSBeiersdorf Implements Sopheon System in Support of Product Innovation Strategy
16th Oct 20077:01 amRNSContract Win
10th Oct 20072:45 pmBUSLeading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System
10th Oct 20077:01 amRNSContract Win
1st Oct 20077:02 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.